Related Experiment Video

Updated: Oct 26, 2025

A Straightforward Method for Glucosinolate Extraction and Analysis with High-pressure Liquid Chromatography HPLC
10:09

A Straightforward Method for Glucosinolate Extraction and Analysis with High-pressure Liquid Chromatography HPLC

Published on: March 15, 2017

25.9K

Correction to "Longisglucinols A-C, Structurally Intriguing Polycyclic Polyprenylated Acylphloroglucinols with

Na Zhang, Zhengyi Shi, Qianqian Xu

    Organic Letters
    |July 28, 2021
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma10:02

    Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

    Published on: June 2, 2023

    2.2K
    Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults14:39

    Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

    Published on: April 22, 2022

    4.1K

    Related Concept Videos

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    330
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    498